

IN THE SPECIFICATION

Please amend the specification in accordance with the following replacement paragraph written in clean form.

Please delete the text beginning immediately after page 5, line 6, below the 'Brief Description of the Drawings' header and ending on Page 8, line 11. Please replace this deleted text with the following new text:

--

Figures 1A and 1B are graphs showing mean dronabinol plasma concentration versus time for treatments A – C (Figure 1A) and D – G (Figure 1B), after single dose administration.

Figures 1C and 1D are graphs showing mean dronabinol plasma concentration versus time for treatments B – C (Figure 1C) and D – G (Figure 1D), after multiple dose administration.

Figure 2A is a graph showing the mean dronabinol plasma concentration versus time on a semi-log scale after single dose administration of treatments A, B and C.

Figure 2B is a graph showing the mean dronabinol plasma concentration versus time on a semi-log scale after single dose administration of treatments D, E, F and G.

Figure 2C is a graph showing the mean dronabinol plasma concentration versus time on a semi-log scale, after multiple dose administration of treatments B and C.

Figure 2D is a graph showing the mean dronabinol plasma concentration versus time on a semi-log scale, after multiple dose administration of treatments D, E, F and G.

Figure 3 is a graph showing dose proportionality assessment following deep-lung inhalation dosing (Treatments B – G) for plasma dronabinol of the First Dose (Day 1) illustrating Cmax/Dose vs. Dose.

Figure 4 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma dronabinol of the First Dose (Day 1) illustrating AUC(0-t)/Dose vs. Dose.

Figure 5 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma dronabinol of the First Dose (Day 1) illustrating AUC(0-inf)/Dose vs. Dose.

Figure 6 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma dronabinol of the Last Dose (Day 5) illustrating Cmax/Dose vs. Dose.

Figure 7 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma dronabinol of the Last Dose (Day 5) illustrating AUC(111-135)/Dose vs. Dose.

Figure 8 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma dronabinol of the Last Dose (Day 5) illustrating Cmin/Dose vs. Dose.

Figure 9 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma dronabinol of the Last Dose (Day 5) illustrating Cavg/Dose vs. Dose.

Figures 10A – 10D are graphs showing mean 11-OH-delta-9-THC plasma concentration versus time on a linear scale after single dose administration of treatments A, B and C (Figure 10A), treatments D, E, F and G (Figure 10B), and after multiple dose administration of treatments B and C (Figure 10C), and treatments D, E, F and G (Figure 10d).

Figure 11 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC of the First Dose (Day 1) illustrating Cmax/Dose vs. Dose.

Figure 12 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC 1 of the First Dose (Day 1) illustrating AUC(0-t)/Dose vs. Dose.

Figure 13 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC of the First Dose (Day 1) illustrating AUC(0-inf)/Dose vs. Dose.

Figure 14 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC of the Last Dose (Day 5) illustrating Cmax/Dose vs. Dose.

Figure 15 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC of the Last Dose (Day 5) illustrating AUC(111-135)/Dose vs. Dose.

Figure 16 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC of the Last Dose (Day 5) illustrating C_{min}/Dose vs. Dose.

Figure 17 is a graph showing dose proportionality assessment following deep-lung inhalation dosing for plasma 11-OH-delta-9-THC of the Last Dose (Day 5) illustrating C_{avg}/Dose vs. Dose.

Figures 18A – 18C are graphs showing mean pulse rate versus time on a linear scale for treatments A, B and C (Figure 18A), treatments D and E (Figure 18B), and treatments F and G (Figure 18C).

Figures 19A – 19C are graphs showing mean conjunctiva congestion scores versus time presented in a linear state for treatments B and C (Figure 19A), treatments D and E (Figure 19B), and treatments F and G (Figure 19C).

Figure 20 is a graph showing the plasma concentration-time profile of dronabinol after single dose administration of dronabinol via oral and pulmonary delivery routes (0-3 hours).

Figure 21 is a graph showing the plasma concentration-time profile of the 11-OH metabolite after single dose administration of dronabinol via oral and pulmonary delivery routes (0-10 hours).

Figure 22 is a graph showing the plasma concentration-time profile of dronabinol after multiple dose administration of dronabinol via pulmonary delivery (0-1 hour).

Figure 23 is a graph showing the plasma concentration-time profile of the 11-OH metabolite after multiple dose administration of dronabinol via pulmonary delivery (0-10 hours).

IN THE DRAWINGS

Please delete Figures 1 – 29 and replace them with the attached replacement set of 36 Drawing Sheets which includes Figures numbered 1A – 1D, 2A – 2D, 3 – 9, 10A – 10D, 11 – 17, 18A – 18B, 19A – 19C, and 20 - 23. In the case of original Figures 1, 2, 3, 11, 12, 20, 21, 23 and 24, Applicants have divided the original data present therein into multiple new figures in order to enhance legibility.